We are live on ! Find out more
ZVSAW

ZyVersa Therapeutics, Inc. Warrants
ZVSAW

Delisted

ZVSAW was delisted on the 20th of December, 2022.

Back to rankings

1 hedge funds and large institutions have $105 invested in ZyVersa Therapeutics, Inc. Warrants in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ZVSAW Hedge Fund Activity: Q1 2023 in Review

1 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics, Inc. Warrants (ZVSAW) for Q1 2023, worth a combined $105.

Fund positioning in ZVSAW was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held ZyVersa Therapeutics, Inc. Warrants (ZVSAW) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $105 of ZyVersa Therapeutics, Inc. Warrants stock for Q1 2023.
  • 0 funds opened new ZyVersa Therapeutics, Inc. Warrants positions in Q1 2023 and 0 closed out.

Based on aggregated 13F filings for Q1 2023.